5-HT1D receptor x 5-HT1B receptor x A1R x A2aR x DRDs x COX - 药物、适应症、专利

基本信息

关联

1

项与 5-HT1D receptor x 5-HT1B receptor x A1R x A2aR x DRDs x COX 相关的药物

Acetaminophen/Caffeine/DIHYDROERGOTAMINE MESYLATE/METOCLOPRAMIDE HYDROCHLORIDE

对乙酰氨基酚/咖啡因/甲磺酸双氢麦角胺/盐酸甲氧氯普胺

靶点

5-HT1B receptor x 5-HT1D receptor x A1R x A2aR x COX x DRDs

作用机制

5-HT1B receptor激动剂 [+5]

在研机构-

原研机构

Aché Laboratórios Farmacêuticos SA

在研适应症-

非在研适应症

偏头痛

最高研发阶段暂停

首次获批国家/地区-

首次获批日期1800-01-20

1

项与 5-HT1D receptor x 5-HT1B receptor x A1R x A2aR x DRDs x COX 相关的临床试验

NCT02582996

/ Suspended临床3期

National, Phase III, Multicenter, Randomized, Open, Parallel, to Evaluate the Efficacy, Safety and Superiority of Cefalium® Compared to the Tylenol® in the Treatment of Migraine Attacks

National clinical trials, phase III, randomized, open, parallel, study of superiority, in which three hundred thirty-six (336) participants of both sexes, aged between 18 and 65 years will be randomly allocated to one of two treatment groups. The Group 01 will use Cefalium® and group 02 will use Tylenol®.

开始日期2020-04-01

申办/合作机构

Aché Laboratórios Farmacêuticos SA

100 项与 5-HT1D receptor x 5-HT1B receptor x A1R x A2aR x DRDs x COX 相关的临床结果

登录后查看更多信息

100 项与 5-HT1D receptor x 5-HT1B receptor x A1R x A2aR x DRDs x COX 相关的转化医学

登录后查看更多信息

0 项与 5-HT1D receptor x 5-HT1B receptor x A1R x A2aR x DRDs x COX 相关的专利（医药）

登录后查看更多信息

分析

对领域进行一次全面的分析。

登录

或

查看完整样例数据